Search Results - "Kwak, Jeff"

Exercise prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity by Evans, Christian C, LePard, Kathy J, Kwak, Jeff W, Stancukas, Mary C, Laskowski, Samantha, Dougherty, Joseph, Moulton, Laura, Glawe, Adam, Wang, Yunwei, Leone, Vanessa, Antonopoulos, Dionysios A, Smith, Dan, Chang, Eugene B, Ciancio, Mae J

“…Diet-induced obesity (DIO) is a significant health concern which has been linked to structural and functional changes in the gut microbiota. Exercise (Ex) is…”
Get full text

Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer by Kleczko, Emily K, Kwak, Jeff W, Schenk, Erin L, Nemenoff, Raphael A

“…Lung cancer is the leading cause of cancer death in men and women. Lung adenocarcinoma (LUAD), represents approximately 40% of all lung cancer cases. Advances…”
Get full text

Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils by Zhang, Huajia, Zhu, Xiaodong, Friesen, Travis J, Kwak, Jeff W, Pisarenko, Tatyana, Mekvanich, Surapat, Velasco, Mark A, Randolph, Timothy W, Kargl, Julia, Houghton, A McGarry

“…Myeloid lineage cells suppress T cell viability through arginine depletion via arginase 1 (ARG1). Despite numerous studies exploring the mechanisms by which…”
Get full text

Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma by Johnson, Amber M, Bullock, Bonnie L, Neuwelt, Alexander J, Poczobutt, Joanna M, Kaspar, Rachael E, Li, Howard Y, Kwak, Jeff W, Hopp, Katharina, Weiser-Evans, Mary C M, Heasley, Lynn E, Schenk, Erin L, Clambey, Eric T, Nemenoff, Raphael A

“…MHC class II (MHCII) expression is usually restricted to APC but can be expressed by cancer cells. We examined the effect of cancer cell-specific MHCII…”
Get full text

Complement Activation via a C3a Receptor Pathway Alters CD4 + T Lymphocytes and Mediates Lung Cancer Progression by Kwak, Jeff W, Laskowski, Jennifer, Li, Howard Y, McSharry, Maria V, Sippel, Trisha R, Bullock, Bonnie L, Johnson, Amber M, Poczobutt, Joanna M, Neuwelt, Alexander J, Malkoski, Stephen P, Weiser-Evans, Mary C, Lambris, John D, Clambey, Eric T, Thurman, Joshua M, Nemenoff, Raphael A

“…The complement cascade is a part of the innate immune system that acts primarily to remove pathogens and injured cells. However, complement activation is also…”
Get full text

CXCR1/2 antagonism inhibits neutrophil function and not recruitment in cancer by Kwak, Jeff W, Nguyen, Helena Q, Camai, Alex, Huffman, Grace M, Mekvanich, Surapat, Kenney, Naia N, Zhu, Xiaodong, Randolph, Timothy W, Houghton, A McGarry

“…The level of tumor and circulating CXCR1/2-expressing neutrophils and CXCR1/2 ligands correlate with poor patient outcomes, inversely correlate with tumoral…”
Get full text

The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade by Li, Howard Y, McSharry, Maria, Bullock, Bonnie, Nguyen, Teresa T, Kwak, Jeff, Poczobutt, Joanna M, Sippel, Trisha R, Heasley, Lynn E, Weiser-Evans, Mary C, Clambey, Eric T, Nemenoff, Raphael A

“…Immune checkpoint inhibitors targeting the interaction between programmed cell death-1 (PD-1) and its ligand PD-L1 induce tumor regression in a subset of…”
Get more information

Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms by Neuwelt, Alexander J, Kimball, Abigail K, Johnson, Amber M, Arnold, Benjamin W, Bullock, Bonnie L, Kaspar, Rachael E, Kleczko, Emily K, Kwak, Jeff W, Wu, Meng-Han, Heasley, Lynn E, Doebele, Robert C, Li, Howard Y, Nemenoff, Raphael A, Clambey, Eric T

“…BackgroundProgrammed death 1/programmed death ligand 1 (PD-1/PD-L1) targeted immunotherapy affords clinical benefit in ~20% of unselected patients with lung…”
Get full text

Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFβ1 by Sippel, Trisha R, Johnson, Amber M, Li, Howard Y, Hanson, Dwight, Nguyen, Teresa T, Bullock, Bonnie L, Poczobutt, Joanna M, Kwak, Jeff W, Kleczko, Emily K, Weiser-Evans, Mary C, Nemenoff, Raphael A

“…Lung cancer is a heterogeneous disease in which patient-specific treatments are desirable and the development of targeted therapies has been effective…”
Get full text

Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC by Bullock, Bonnie L, Kimball, Abigail K, Poczobutt, Joanna M, Neuwelt, Alexander J, Li, Howard Y, Johnson, Amber M, Kwak, Jeff W, Kleczko, Emily K, Kaspar, Rachael E, Wagner, Emily K, Hopp, Katharina, Schenk, Erin L, Weiser-Evans, Mary Cm, Clambey, Eric T, Nemenoff, Raphael A

“…Targeting PD-1/PD-L1 is only effective in ∼20% of lung cancer patients, but determinants of this response are poorly defined. We previously observed…”
Get full text

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity by Kleczko, Emily K., Hinz, Trista K., Nguyen, Teresa T., Gurule, Natalia J., Navarro, Andre, Le, Anh T., Johnson, Amber M., Kwak, Jeff, Polhac, Diana I., Clambey, Eric T., Weiser-Evans, Mary, Merrick, Daniel T., Yang, Michael C., Patil, Tejas, Schenk, Erin L., Heasley, Lynn E., Nemenoff, Raphael A.

“…Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g., alectinib), with variation in the degree of…”
Get full text

Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II by Li, Howard Y., McSharry, Maria, Walker, Deandra, Johnson, Amber, Kwak, Jeff, Bullock, Bonnie, Neuwelt, Alexander, Poczobutt, Joanna M., Sippel, Trisha R., Keith, Robert L., Weiser-Evans, Mary C. M., Clambey, Eric, Nemenoff, Raphael A.

“…Lung-specific overexpression of prostacyclin synthase (PGIS) decreases tumor initiation in murine lung cancer models. Prostacyclin analogs prevent lung tumor…”
Get full text

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC by Singleton, Katherine R, Hinz, Trista K, Kleczko, Emily K, Marek, Lindsay A, Kwak, Jeff, Harp, Taylor, Kim, Jihye, Tan, Aik Choon, Heasley, Lynn E

“…The FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical trials of selective tyrosine kinase inhibitors (TKI) are underway…”
Get full text

Tumor cell-intrinsic MHC class II expression as a determinant of immunotherapy responsiveness in an orthotopic mouse model of non-small cell lung cancer by Clambey, Eric T., Johnson, Amber M., Neuwelt, Alex, Kimball, Abigail K., Kaspar, Rachael, Bullock, Bonnie, Kwak, Jeff, Poczobutt, Joanna, Li, Howard, Nemenoff, Raphael

“…Lung cancer is the leading cause of cancer-related deaths worldwide and the second most common cancer among both men and women in the United States…”
Get full text

Exercise Prevents Weight Gain and Alters the Gut Microbiota in a Mouse Model of High Fat Diet-Induced Obesity: e92193 by Evans, Christian C, LePard, Kathy J, Kwak, Jeff W, Stancukas, Mary C, Laskowski, Samantha, Dougherty, Joseph, Moulton, Laura, Glawe, Adam, Wang, Yunwei, Leone, Vanessa

“…Background Diet-induced obesity (DIO) is a significant health concern which has been linked to structural and functional changes in the gut microbiota…”
Get full text